Lymphoma and plasma cell neoplasms
Non-Hodgkin lymphoma
Cytogenetics

Author: Nikhil Sangle, M.D. (see Authors page)

Revised: 3 March 2017, last major update February 2011

Copyright: (c) 2001-2017, PathologyOutlines.com, Inc.

PubMed Search: cytogenetics non-hodgkin lymphoma

Table of Contents
Translocations
Cite this page: Cytogenetics. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/lymphomacyto.html. Accessed July 26th, 2017.
Translocations
Relatively common translocations are listed below (see each topic for more complete lists):
  • t(1;14)(p22;q32): BCL10 and IgH; MALT lymphoma (% unknown)
  • t(1;14)(p32;q11): SCL (tal-1) and T cell receptor delta / alpha; pre T-ALL (15 - 30%)
  • t(1;14)(q21;q32); BCL9 and IgH; pre B-ALL (acute lymphoblastic leukemia / lymphoma), mantle cell lymphoma
  • t(1;19)(q23;p13): PBX1 and E2A; pre B-ALL (30%)
  • t(2;5)(p23;q35): ALK and NPM; anaplastic large cell lymphoma, T / NK subtypes (40 - 70%)
  • t(2;8)(p12;q24): Ig Kappa and c-MYC; Burkitt lymphoma (15%)
  • t(2;18)(p12;q21): Ig Kappa and BCL2; follicular lymphoma (< 5%)
  • Trisomy 3: MALT lymphoma (% unknown)
  • t(3;14)(q27;q32): BCL6 and IgH; diffuse large B cell lymphoma (30%), follicular lymphoma (10%)
  • t(4;11)(q21;q23): AF4 and MLL; pre B-ALL (10%)
  • t(4;14)(p16.3;q32): FGFR3 / mmset and IgH; multiple myeloma (25 - 30%)
  • t(5;14): IL3 gene and IgH; pre B-ALL and peripheral eosinophilia
  • t(6;14)(p25;q32): MUM1 / IRF4 and IgH; multiple myeloma
  • 7q isochromosome: hepatosplenic gamma / delta lymphoma (% unknown)
  • Trisomy 8: hepatosplenic gamma / delta lymphoma (% unknown)
  • t(8;13)(p11;q11-12): FGFR1 and ZNF 198; T cell lymphoblastic with eosinophilia (% unknown)
  • t(8;14)(q24;q32): c-MYC and IgH; Burkitt lymphoma (75%), ALL-type L3 (6%)
  • t(8;21): ETO gene and AML1 gene; AML-M2
  • t(8;22)(q24;q11): c-MYC and Ig Lambda; Burkitt lymphoma (10%)
  • 9p amplification: REL; primary mediastinal large B cell lymphoma (% unknown)
  • t(9;14)(p13;q32): PAX5 and IgH; lymphoplasmacytic lymphoma (% unknown)
  • t(9;22)(q34;q11): c-ABL and BCR (Philadelphia chromosome); pre B-ALL (5% of children, 25% of adults), chronic myelogenous leukemia (about 95%, controversial)
  • t(10;14)(q24;q11): HOX11 and T cell receptor delta / alpha; pre T-ALL (7%)
  • Deletion of 11q23: CLL (10 - 20%)
  • t(11;14)(q13;q32): BCL1 / PRAD1 and IgH; mantle cell lymphoma (90%), B cell prolymphocytic leukemia (20%), myeloma (3%)
  • t(11;14): rhombotin 1/2 genes and IgH; T-ALL
  • t(11;18)(q21;q21): API2 and MLT; MALT lymphoma (50%)
  • Trisomy 12: B-CLL (30%)
  • t(12;21)(p13;q22): ETV6-CBFA2 (TEL and AML1); pre B-ALL (20%)
  • Deletion 13q14: B-CLL (25 - 50%)
  • Inversion 14(q11;q32) or other #14 translocations: T cell prolymphocytic leukemia (75%)
  • t(14;15)(q32;q11-13); IgH and BCL8; diffuse large B cell lymphoma (3%)
  • t(14;16)(q32;q23); IgH and c-Maf; multiple myeloma
  • t(14;18)(q32;q21): IgH and BCL2; follicular lymphoma (90%), diffuse large B cell lymphoma (30%)
  • t(14;19)(q32;q13): IgH and BCL3; B-CLL
  • t(15;17): retinoic acid receptor and PML gene; acute prolymphocytic leukemia, M3 (most)
  • t(16;22);(q23;q11): c-Maf and Ig lambda; multiple myeloma
  • Trisomy 18: common in marginal zone lymphoma, MALT type